Picture loading failed.

Pre-Made Tisotumab biosimilar, Whole mAb, Anti-F3 Antibody: Anti-CD142/TF/TFA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tisotumab vedotin, also known as HuMax-TF, HuMax®-TF-ADC or TF-011-MMAE, is an antibody-drug conjugate or ADC targeted to Tissue Factor (TF), a protein involved in tumor signaling and angiogenesis.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-582-1mg 1mg 3090
GMP-Bios-ab-582-10mg 10mg 21890
GMP-Bios-ab-582-100mg 100mg 148000
GMP-Bios-ab-582-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Tisotumab biosimilar, Whole mAb, Anti-F3 Antibody: Anti-CD142/TF/TFA therapeutic antibody
INN Name Tisotumab
TargetF3
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesGenmab;Seattle Genetics
Conditions Approvedna
Conditions ActiveBladder cancer;Cervical cancer;Endometrial cancer;Fallopian tube cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Solid tumours
Conditions Discontinuedna
Development Techna